Products for Research Use Only
RegisterLogin

Linzagolix

CAT: 0931-T27837-03Size: 1 mL - 10 mM (in DMSO)Dry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0931-T27837-03Size:1 mL - 10 mM (in DMSO)
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
CAS Number
935283-04-8
Target
GNRH Receptor
Related Pathways
GPCR/G Protein
Purity
0.9968
Bioactivity
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Smiles
COc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
Molecular Formula
C22H15F3N2O7S
Molecular Weight
508.42
Shipping Conditions
Ice Packs
Storage Temperature
-20°C

Chemical Information

Linzagolix

Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix]. Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency, and reproductive dysfunction. As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by preventing intramyometrial growths in the endometrial glands. Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.

CAS Number935283-04-8
PubChem CID16656889
IUPAC Name3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid
Molecular FormulaC22H15F3N2O7S
Molecular Weight508.4
XLogP3.4
Topological Polar Surface Area143
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count7
Heavy Atom Count35
Formal Charge0
Complexity826
SMILES
COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC
InChI
InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
InChIKey
BMAAMIIYNNPHAB-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Linzagolix
CAS: 935283-04-8
CID: 16656889
Formula: C22H15F3N2O7S
MW: 508.4
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight508.4
XLogP33.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count7
Exact Mass508.05520648
Monoisotopic Mass508.05520648
Topological Polar Surface Area143 Ų
Heavy Atom Count35
Formal Charge0
Complexity826
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
BUP02769-01Linzagolix
HY-120767Linzagolix (choline)
M34100-01Linzagolix choline
RM-L230003-01Linzagolix Impurity 3
RM-L230002-01Linzagolix Impurity 2
RM-L230006-01Linzagolix Impurity 6
RM-L230004-01Linzagolix Impurity 4
RM-L230001-01Linzagolix Impurity 1
RM-L230005-01Linzagolix Impurity 5

Popular Products